Mephentermine
Reading File
Finding Sources
Searching PubMed
mephentermine vasopressor pharmacology
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
I have enough from Goodman & Gilman and the other sources. Let me now compile the full answer.
Mephentermine
Drug Class & Basic Profile
Mephentermine is a sympathomimetic amine with mixed direct and indirect adrenergic activity. It acts on both α and β adrenergic receptors - it stimulates α₁ receptors directly and also acts indirectly by releasing endogenous norepinephrine (NE) from presynaptic nerve terminals.
- Goodman & Gilman's classifies it as: "acts both directly and indirectly," alongside metaraminol, as an α adrenergic receptor agonist used for hypotension
- Chemically, it is a derivative of amphetamine (alongside methamphetamine, dextroamphetamine, phentermine, and methylphenidate)
Mechanism of Action
| Pathway | Effect |
|---|---|
| Direct α₁ activation | Vasoconstriction - raises peripheral vascular resistance (PVR) |
| Direct β₁ activation | Positive inotropic and chronotropic effects on the heart |
| Indirect: NE release | Further amplifies both α and β effects |
| CNS stimulation | Mild stimulant effect (amphetamine derivative) |
Because it releases stored NE, its effects can be attenuated in patients who are catecholamine-depleted (e.g., on reserpine, or after prolonged sympathetic stimulation).
Pharmacological Effects
Cardiovascular:
- Raises blood pressure primarily by increasing cardiac output (positive inotropy + chronotropy via β₁) and to a lesser extent by vasoconstriction (α₁)
- Heart rate may increase (β₁) or remain unchanged depending on dose and reflex responses
- Unlike pure α agonists (e.g., phenylephrine), it does not typically cause reflex bradycardia because its β effects dominate the primary response
- Renal and splanchnic blood flow effects are less severe than with pure α agonists
Uterine blood flow:
- Studies in pregnant ewes (Ralston et al., 1974, cited in Miller's Anesthesia) compared mephentermine with ephedrine, metaraminol, and methoxamine on uterine blood flow - a key consideration in obstetric anesthesia
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Route | IV bolus or IM; also oral (limited use) |
| Onset | Rapid (minutes) after IV |
| Duration | 30-60 minutes (longer than ephedrine) |
| Metabolism | Hepatic (N-demethylation) |
| Excretion | Renal |
Clinical Uses
1. Hypotension - Primary Indication
Mephentermine is used to treat and prevent hypotension, particularly in the following settings:
- Spinal/epidural anesthesia-induced hypotension - one of its most common clinical uses, especially in obstetrics (cesarean section)
- Drug-induced hypotension (e.g., after antihypertensive overdose)
- Shock states - listed among the α agonists used when severe hypotension compromises CNS perfusion (alongside NE, phenylephrine, ephedrine, EPI, DA, methoxamine, and midodrine) per Goodman & Gilman's
2. Obstetric Anesthesia
Mephentermine has historically been popular in South Asia (India especially) as a vasopressor for post-spinal hypotension during cesarean delivery. It is compared to ephedrine in this role - both preserve uteroplacental blood flow better than pure α agonists, though recent trials are comparing it against phenylephrine and norepinephrine as first-line agents.
Comparison with Related Drugs
| Drug | Mechanism | HR effect | Preferred use |
|---|---|---|---|
| Mephentermine | Mixed α+β, direct + indirect | ↑ or neutral | Spinal hypotension, shock |
| Ephedrine | Mixed α+β, direct + indirect | ↑ | Spinal hypotension (classic) |
| Phenylephrine | Pure α₁ direct | ↓ (reflex brady) | Spinal hypotension (modern preference) |
| Norepinephrine | α₁ >> β₁ | ↓ (reflex) | Septic shock, SpHypo |
| Metaraminol | Direct α₁ + indirect NE release | ↓ | Hypotension |
Adverse Effects
- Hypertension - if dose is excessive
- Tachycardia and palpitations
- CNS excitation - due to amphetamine-related structure: anxiety, restlessness
- Arrhythmias - particularly in the setting of halothane anesthesia (sensitizes myocardium)
- Tachyphylaxis - with repeated dosing (NE stores deplete)
- In cardiogenic shock: may worsen outcomes by increasing afterload and myocardial oxygen demand
Contraindications / Cautions
- Concurrent use with MAO inhibitors - risk of hypertensive crisis (indirect sympathomimetic mechanism)
- Halothane anesthesia - myocardial sensitization to arrhythmias
- Hypertension, coronary artery disease - risk of adverse cardiovascular effects
- Hyperthyroidism - exaggerated response
- Caution in cardiogenic shock (as with all pure vasoconstrictors)
Recent Evidence (2025-2026)
Two recent RCTs are directly relevant:
-
Mephentermine vs. norepinephrine infusion for prevention of post-spinal hypotension during elective cesarean delivery: Mohta M et al. (2025), Int J Obstet Anesth [PMID: 39426031] - a randomized, double-blind trial comparing the two agents.
-
Relative potency of norepinephrine vs. mephentermine bolus for spinal hypotension during cesarean delivery: Mohta M et al. (2025), Int J Obstet Anesth [PMID: 40701126] - an up-down sequential allocation study establishing relative ED₅₀ dosing.
-
Network meta-analysis of vasopressor infusions for feto-maternal outcomes in cesarean delivery: Singh NP et al. (2026), Anaesthesia [PMID: 41854017] - includes mephentermine among comparators.
These trials reflect ongoing interest in comparing mephentermine's performance against newer vasopressors (particularly phenylephrine and norepinephrine) in obstetric anesthesia, where fetal acid-base status is a key outcome.
Summary
Mephentermine is a mixed direct/indirect α+β sympathomimetic that raises BP primarily by increasing cardiac output (unlike pure vasoconstrictors). It is particularly used in India and South Asia for post-spinal hypotension in obstetric settings. Its amphetamine-related structure confers mild CNS stimulation and the potential for tachyphylaxis. It has largely been replaced in Western practice by phenylephrine and norepinephrine for spinal hypotension, but remains clinically relevant where those agents are unavailable.
- Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 279 (α adrenergic agonists section)
- Goodman & Gilman's, p. 286 (Shock - therapeutic uses)
- Miller's Anesthesia, 10e (uterine blood flow in obstetric anesthesia context)
This is a shared conversation. Sign in to Orris to start your own chat.